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The age of the population is constantly increasing. Epidemiological studies show that 11% of the world’s popula-
tion is over 60 years old, with an expected increase, in 2050, to 22%1. As aging is often associated with the develop-
ment of the disease, this leads to an increase in age-related pathological conditions, such as cancer, cardiovascular 
and neurodegenerative diseases. In addition to environmental and lifestyle factors, it is well known that both 
genetic and epigenetic aspects play a central role in the development of these diseases2.
In recent years, most of the attention has been focused on the genes of the circadian clock, a series of genes 
involved in maintaining the internal coordination of multiple oscillators within and between various organs sys-
tems, in order to increase the physical fitness of an organism and provide the most efficient response to the 
periodical environmental events such as the day/night cycle3. The Circadian Locomotor Output Cycles Kaput 
(CLOCK) gene is one of the first genes studied in this regard: it codifies for the CLOCK protein, a positive regu-
latory arm of the circadian system. The alterations of this complex system – that is shift work, sleep deprivation, 
exposure to intense light at night, as well as the physiological process of aging – or genetic variation of the CLOCK 
gene, have been associated with several physiological and pathological conditions. In particular, variations of the 
CLOCK gene have been associated with the risk of obesity, type 2 diabetes, sleep and mood disorders, and differ-
ent types of cancer4–6. With regard to aging, few studies have investigated the possible role of the CLOCK gene on 
longevity7,8, but to the best of our knowledge, no studies have investigated the possible influence of CLOCK gene 
SNPs on the quality of aging in very elderly subjects.
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The aim of the present study was to investigate the relationship between three common polymorphisms 
known in the CLOCK gene and the aging process, in relation to cardiovascular risk factors, quality of sleep, adher-
ence to the Mediterranean diet, as well as cognitive and functional skills, in a cohort of nonagenarians enrolled in 
the frame of an epidemiological study conducted in the Mugello area, Tuscany, Italy9.
Material and Methods
Study population.  The study population consisted of 356 elderly subjects [257 women, 99 men; median age 
92 (88–106) years] enrolled in the Mugello study, an epidemiological study aimed at investigating some clinically 
relevant geriatric items related to the quality of aging, as well as various health issues including those related to the 
nutritional status of a group of nonagenarians living in the Mugello area, Tuscany, Italy. The details of the study 
protocol and the characteristics of the study population have been described elsewhere9. The study was conducted 
according to the Helsinki Declaration on Clinical Research involving Human Subjects and was approved by the 
Ethics Committee of the Don Gnocchi Foundation. All participants, or their legal representative, have signed the 
informed consent form.
Data collection and measurements.  Demographic characteristics. The subjects enrolled were evaluated 
during home visits/nursing home, through objective examinations and questionnaires regarding lifestyle, dietary 
habits and cognitive status. General information on demographics, education, personal medical history and drug 
use was collected by each participant. After the subjects were rested for 5 minutes in a quiet room, arterial systolic 
and diastolic blood pressure were measured on the right arm with a standard mercury sphygmomanometer while 
the subjects were sitting in a sitting position. After 12 hours of nocturnal fasting, venous blood samples were 
obtained from participants. Laboratory parameters were analyzed using standard procedures.
Anthropometric measurements. Anthropometric data, such as weight, height and waist circumference were 
collected by the participants. The body mass index (BMI) was calculated as the weight in kilograms divided 
by height in square metres. The classification of the World Health Organization for the categories of BMI, in 
terms of underweight (BMI < 18.5), normal weight (BMI = 18.5–24.9), overweight (BMI = 25.0–29.9) and obese 
(BMI ≥ 30) was used to classify the patients.
Sleep pattern determination. The sleep pattern of patients was assessed using the Pittsburgh Sleep Quality Index 
(PSQI)10, which is a validated self-assessed questionnaire comprising nineteen individual elements that generate 
seven scores related to sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, 
use of sleep medications, and daytime dysfunction. The score of the answers is based on a scale from 0 to 3, in 
which 3 reflects the extreme negative. A global sum of “5” or greater indicates a “poor” sleeper. The sleep pattern 
information was also collected by using a SenseWear Armband calorimeter (BodyMedia Inc, USA), applied to the 
participants over the triceps muscle, halfway between the acromion and the olecranon processes, as suggested by 
the manufacturer. The participants were asked to wear ArmBand for at least a week, removing it only for bathing 
or showering.
Cognitive and functional abilities determination. Regarding cognitive skills, a shorter version of the Geriatric 
Depression Scale (GDS)11, consisting of 15 items, was used to detect the possible presence of depressive symp-
toms. Scores ≥5 were considered indicative of depression. The cognitive impairment comprising the memory, 
orientation, attention and language of the participants was evaluated by the Mini Mental State Examination 
(MMSE)12: the overall score ranged from 0 and 30 and a score of 23 or less was used to indicate cognitive impair-
ment. In addition, a Clock Drawing Test (CDT)13 was used, with a global score ranging from 0 (without cogni-
tive impairment) to 10 (prominent cognitive impairment), to investigate visuo-constructional skills and abstract 
thinking. Functional ability was assessed using the Basic Activities of Daily Living (BADL)14 – with a total score 
ranging from 0 (independence in all functions) to 6 (complete dependence) – and the Instrumental Activities 
of Daily Living (IADL)15 – with a total score between 0 (complete independence) to 8 (complete dependence). 
Finally, the Frailty Index 34 (FI-34)16 was used to measure the health status of older individuals using a series of 
34 aging-related variables as a substitute for aging and vulnerability to negative outcomes: the overall score ranged 
from 0 (no frailty) to 1 (prominent frailty).
Dietary evaluation. The dietary intake was evaluated through the Mediterranean Diet Score, devised by 
Panagiotakos et al.17. The questionnaire consisted of 11 items, with a global score ranging from 0, for a minimal 
adherence to the traditional Mediterranean Diet, to 55 for maximum adherence.
CLOCK Genotyping.  We selected tag single nucleotide polymorphisms (tag SNPs) as effective proxies for 
untyped SNPs in strong linkage disequilibrium (LD) using the Tagger-pairwise Tagging algorithm (HapMap 
database and software available at http://hapmap.ncbi.nlm.nih.gov) on the CLOCK gene based on Caucasian 
European Utah data with a minor allele frequency (MAF) ≥0.20 and a minimum r2 of 0.8. The following SNPs 
have been selected: rs3736544, rs11932595 and rs17722979. Based on information on linkage disequilibrium and 
previous reports showing associations with cardio-metabolic outcomes, rs17722979 was replaced by rs1801260 
(known as 3111T/C), and rs3736544 was replaced by rs4580704. For haplotype analysis, we estimated haplotype 
frequencies using expectation-maximization algorithm implemented in HelixTree software (GOLDEN Helix, 
Bozeman, MN).
DNA was isolated from blood samples using Flexigene DNA kit (Qiagen, Hilden, Germany). We performed 
genotyping of CLOCK gene polymorphisms using a TaqMan assay with allele-specific probes (ThermoFisher 
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Scientific) on the ABI Prism 7900HT Sequence Detection System (Applied Biosystem, Foster City, CA, USA) 
according to the standardized laboratory protocol18.
Statistical analysis.  Statistical analysis was performed using the SPSS (Chicago, IL) software for Macintosh 
(version 19.0). Values are expressed as mean and 95% Confidence Interval (CI). Log-transformed values for all 
the parameters were used in the analyses and back transformed for data presentation. Different genetic inher-
ent models were tested, and a recessive model was applied in the final analyses for all the selected SNPs. The 
chi-square test was used to test for deviations of genotype distributions from the Hardy–Weinberg equilibrium 
(HWE), to detect any differences in genotype distributions based on sex and to detect any differences in propor-
tions – e.g. sex distribution, categories of BMI and adherence to the Mediterranean Diet – according to genotype. 
The associations between the different genotypes and the general characteristics of the study population was 
tested using the analysis of variance (ANOVA) adjusted for all the possible confounding factors. Furthermore, in 
order to estimate the association between haplotypes and all the variables tested, a logistic regression analysis was 
performed adjusted for age, sex, BMI (as continuous variable) and specific medication (statins for lipid parame-
ters; beta-blockers, diuretics, calcium antagonists and ACE-inhibitors for blood pressure; anti-diabetic drugs and 
insulin for blood glucose; antidepressants for depression, and benzodiazepines for cognitive parameters and sleep 
pattern). Odds ratio (OR) with 95% CI was determined. A p-value < 0.05 was considered statistically significant.
Results
Genotype distributions.  Genotype distributions and allele frequencies of rs1801260, rs11932595 and 
rs4580704 polymorphisms were in Hardy-Weinberg equilibrium and are summarized in Table 1. No significant 
differences were reported for genotype distribution and allele frequency between women and men.
Characteristics of the study participants.  The demographic and clinical characteristics of the study 
participants, according to the genotype, are described in Table 2. Regarding the anthropometric parameters, a 
significant difference in the prevalence of overweight people based on the presence of the homozygous genotype 
for the minor allele of rs1801260 (GG: 16.1% vs. AA + AG: 33.7%; p = 0.046) was observed. As of biochemi-
cal parameters, after adjustment for medications, subjects homozygous for the minor allele of rs1801260 and 
rs11932595 showed higher fasting glucose levels (GG: 101.25 (95%CI 93.71–108.79) vs. AA + AG: 92.81 (95%CI 
90.33–95.29) mg/dL; p = 0.037 and GG: 99.36 (95%CI 93.22–105.51) vs. AA + AG: 92.51 (95%CI 89.90–95.12) 
mg/dL; p = 0.044, respectively) compared to those heterozygous and homozygous wild-type. On the other hand, 
subjects homozygous for the minor allele of rs4580704 showed higher blood triglyceride and LDL-cholesterol 
levels than those heterozygous and homozygous wild-type (GG: 131.55 (95%CI 116.90–146.20) vs. CC + CG: 
111.36 (105.65–117.07) mg/dL; p = 0.012 and GG: 120.81 (95%CI 111.40–130.22) vs. CC + CG: 110.41 (106.74–
114.08) mg/dL; p = 0.044). Regarding cognitive and functional abilities, after adjustment for medications, people 
homozygous for the minor allele of rs1801260 and rs11932595 showed a better score in the clock drawing test 
(GG: 3.19 (95%CI 1.89–4.49) vs. AA + AG: 4.59 (95%CI 4.15–5.02); p = 0.047 and GG: 3.34 (95%CI 2.28–4.39) 
vs. AA + AG: 4.61 (4.15–5.07); p = 0.030, respectively) compared to subjects heterozygous and homozygous 
wild-type, whereas people homozygous for the minor allele of rs1801260 showed a worse score on the geriatric 
depression scale than heterozygous and homozygous wild-type (GG: 6.32 (95%CI 4.78–7.86) vs. AA + AG: 4.54 
(4.03–5.05); p = 0.032). Finally, as regards adherence to the Mediterranean diet a larger number of adherent (with 
a score ≥34, or median for the study population) were homozygous for the minor allele of rs4580704 compared 
to heterozygous and homozygous wild-type (GG: 72.7% vs. AA + AG: 56.7%; p = 0.044).
Haplotype analysis.  Figure 1 shows the LD plot among the three polymorphisms of the CLOCK gene. 
Haplotype reconstruction analysis for the CLOCK gene indicated that the haplotypes of AAC, AAG, GGC and 
Genotype Allele All Women Men p
rs1801260 n = 355 n = 257 n = 98
AA 168 (47.3) 119 (46.3) 49 (50.0)
0.385AG 153 (43.1) 110 (42.8) 43 (43.9)
GG 34 (9.6) 28 (10.9) 6 (6.1)
G 0.311 0.323 0.281 0.426
rs11932595 n = 344 n = 247 n = 97
AA 114 (33.1) 79 (32.0) 35 (36.1)
0.222AG 176 (51.2) 124 (50.2) 52 (53.6)
GG 54 (15.7) 44 (17.8) 10 (10.3)
G 0.413 0.429 0.371 0.366
rs4580704 n = 351 n = 255 n = 96
CC 149 (42.5) 115 (45.1) 34 (35.4)
0.262CG 156 (44.4) 108 (42.4) 48 (50.0)
GG 46 (13.1) 32 (12.5) 14 (14.6)
G 0.354 0.337 0.396 0.322
Table 1. Genotype distributions and allele frequencies of the investigated polymorphism.
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AGC (rs1801260 – rs11932595 – rs4580704) had frequencies of 30.4%, 24.8%, 22.4% and 22.3% respectively. To 
test any possible association between haplotypes and the tested variables, a logistic regression analysis adjusted 
for possible confounding factors (e.g. age, sex, BMI and medications) was performed (Supplementary Table 1). 
The AAG haplotype was associated with a higher risk of overweight (OR = 1.816, 95%CI 1.169–2.821; p = 0.008), 
hypertriglyceridemia (OR = 1.857, 95%CI 1.029–3.351; p = 0.040), and hypercholesterolemia (OR = 1.663, 
95%CI 1.034–2.674; p = 0.036). The GGC haplotype was associated with lower risk of hyperglycemia, com-
paring people with higher fasting glucose levels (ie >110) to people with low fasting glucose levels (ie ≤110) 
(OR = 0.426, 95% CI 0.205–0.884; p = 0.022). Furthermore, categorizing people based on scores obtained in PSQI 
(>7, ie worsening of the sleep pattern compared to ≤7, ie better sleep pattern) and MMSE (>22, or better score 
vs. ≤22, or worse score), the GGC haplotype was associated with a better sleep pattern (OR = 0.419 95% CI 
0.254–0.692; p = 0.001) and with a better score at the MMSE (OR = 0.530, 95% CI 0.327–0.861; p = 0.010). In 
addition, subjects were classified in depressed and non-depressed based on the GDS score (scores ≥ 5 were con-
sidered indicative of depressive status, whereas scores <5 were considered indicative of non-depressive state): the 
AGC haplotype determined a lower risk of depression (OR = 0.552, 95% CI 0.328–0.931; p = 0.026). Finally, con-
sidering adherent those who scored ≥34 points in the MedDiet Score and non-adherent individuals who scored 
<34 point (ie the median score obtained in the entire study population), the AAC haplotype was associated with 
a lower degree of adherence to the Mediterranean diet (OR = 1.735, 95% CI 1.061–2.836; p = 0.028).
rs1801260 rs11932595 rs4580704
AA + AG (n = 321) GG (n = 34) p AA + AG (n = 290) GG (n = 54) p CC + CG (n = 305) GG (n = 46) p
Anthropometric parameters
Female, n (%) 229 (71.3) 28 (82.4) 0.226 203 (70) 44 (81.5) 0.099 223 (73.1) 32 (69.6) 0.723
Age*, years 93.01 (92.66–93.37) 92.32 (91.23–93.42) 0.240 93.09 (92.72–93.47) 92.39 (91.52–93.26) 0.146 93.03 (92.67–93.40) 92.13 (91.19–93.07) 0.078
Weight*, kg 62.76 (61.34–64.18) 62.00 (57.54–66.46) 0.748 63.01 (61.51–64.52) 61.66 (58.13–65.19) 0.487 62.27 (60.81–63.77) 65.06 (61.28–68.85) 0.177
Height*, m 1.58 (1.57–1.59) 1.58 (1.55–1.61) 0.868 1.58 (1.57–1.59) 1.58 (1.55–1.60) 0.908 1.57 (1.56–1.58) 1.60 (1.57–1.62) 0.105
Waist circumference*, 
cm 96.48 (95.08–97.88) 95.38 (91.01–99.74) 0.637 96.67 (95.20–98.15) 95.42 (91.93–98.92) 0.516 96.08 (94.64–97.52) 97.57 (93.84–101.30) 0.464
BMI*, kg/m2 25.21 (24.70–25.72) 24.84 (23.25–26.44) 0.667 25.30 (24.76–25.84) 24.78 (23.52–26.04) 0.455 25.11 (24.58–25.63) 25.62 (24.24–26.99) 0.494
<18.5, n (%) 18 (6.0) 1 (3.2) 0.527 17 (6.3) 2 (4.1) 0.748 15 (5.2) 4 (10.0) 0.267
18.5–24.9, n (%) 139 (46.3) 20 (64.5) 0.054 124 (45.8) 28 (57.1) 0.162 144 (50.0) 14 (35.0) 0.091
25–29.9, n (%) 101 (33.7) 5 (16.1) 0.046 91 (33.6) 12 (24.5) 0.246 90 (31.3) 14 (35.0) 0.633
>30, n (%) 42 (14.0) 5 (16.1) 0.530 39 (14.4) 7 (14.3) 0.999 39 (13.5) 8 (20.0) 0.275
Biochemical parameters
Triglycerides*, mg/dl 112.80 (107.18–118.42) 123.32 (106.23–140.40) 0.251 112.16 (106.32–118.01) 117.49 (103.75–131.24) 0.484 111.36 (105.65–117.07) 131.55 (116.90–146.20) 0.012
Total cholesterol*, mg/dl 192.07 (187.51–196.64) 198.96 (185.08–212.83) 0.354 193.00 (188.17–197.83) 193.30 (181.93–204.67) 0.962 191.13 (186.50–195.77) 203.76 (191.87–215.65) 0.052
LDL cholesterol*, mg/dl 111.73 (108.13–115.34) 114.30 (103.34–125.26) 0.663 112.83 (109.03–116.63) 109.02 (100.08–117.95) 0.440 110.41 (106.74–114.08) 120.81 (111.40–130.22) 0.044
HDL cholesterol*, mg/dl 57.78 (55.89–59.66) 59.99 (54.27–65.72) 0.469 57.74 (55.76–59.72) 60.79 (56.13–65.45) 0.237 58.45 (56.53–60.38) 56.63 (51.69–61.56) 0.498
Fasting glucose*, g/L 92.81 (90.33–95.29) 101.25 (93.71–108.79) 0.037 92.51 (89.90–95.12) 99.36 (93.22–105.51) 0.044 94.43 (91.86–96.99) 89.14 (82.51–95.77) 0.145
Blood pressure
Systolic blood pressure*, 
mmHg 134.03 (131.84–136.21) 132.63 (125.83–139.43) 0.701 133.34 (131.11–135.56) 134.07 (128.79–139.35) 0.802 134.21 (131.98–136.43) 130.26 (124.43–136.10) 0.215
Diastolic blood 
pressure*, mmHg 72.11 (71.10–73.12) 73.44 (70.29–76.59) 0.430 71.89 (70.85–72.95) 74.10 (71.60–76.61) 0.112 72.23 (71.19–73.26) 71.34 (68.63–74.06) 0.550
Sleep pattern
PSQI*, score 7.19 (6.79–7.59) 6.91 (5.64–8.17) 0.672 7.16 (6.73–7.59) 7.11 (6.15–8.07) 0.923 7.15 (6.74–7.56) 7.41 (6.27–8.54) 0.675
Time in bed*, min/day 608.24 (584.32–632.16) 654.95 (581.77–728.14) 0.232 612.61 (586.92–638.29) 623.80 (563.43–684.18) 0.736 617.54 (592.51–642.57) 584.31 (523.90–644.71) 0.317
Sleep duration*, min/
day 495.98 (474.52–517.44) 536.66 (471.00–602.31) 0.246 499.13 (475.96–522.30) 502.20 (447.74–556.66) 0.918 505.87 (483.55–528.18) 462.09 (408.23–515.95) 0.140
Time to fall asleep*, 
min/day 112.26 (100.66–123.86) 118.30 (82.80–153.79) 0.750 113.48 (100.98–125.98) 121.60 (92.21–150.99) 0.616 111.67 (99.60–123.74) 122.22 (93.09–151.34) 0.510
Cognitive and functional abilities
Clock drawing test*, 
score 4.59 (4.15–5.02) 3.19 (1.89–4.49) 0.047 4.61 (4.15–5.07) 3.34 (2.28–4.39) 0.030 4.48 (4.03–4.92) 4.47 (3.27–5.66) 0.989
GDS*, score 4.54 (4.03–5.05) 6.32 (4.78–7.86) 0.032 4.53 (3.99–5.07) 5.62 (4.36–6.88) 0.119 4.72 (4.20–5.23) 4.50 (3.12–5.88) 0.774
MMSE*, score 18.92 (17.93–19.90) 20.82 (17.81–23.83) 0.238 18.83 (17.79–19.87) 20.42 (18.02–22.82) 0.232 19.32 (18.32–20.32) 17.97 (15.33–20.61) 0.348
BADL*, score 2.32 (2.06–2.58) 2.39 (1.60–3.19) 0.861 2.38 (2.11–2.66) 2.12 (1.48–2.75) 0.447 2.39 (2.12–2.65) 2.00 (1.32–2.68) 0.299
IADL*, score 4.13 (3.76–4.51) 4.32 (3.19–5.46) 0.756 4.17 (3.77–4.57) 4.06 (3.14–4.98) 0.830 4.21 (3.82–4.59) 3.77 (2.76–4.77) 0.423
Frailty index*, score 0.21 (0.19–0.22) 0.20 (0,16–0.24) 0.642 0.21 (0.19–0.22) 0.22 (0.19–0.25) 0.345 0.21 (0.20–0.22) 0.21 (0.18–0.24) 0.945
Dietary evaluation
Med Diet Score*, 
mean ± SD 34.08 (33.66–34.49) 34.35 (33.07–35.63) 0.685 34.08 (33.64–34.52) 34.13 (33.12–35.14) 0.929 33.98 (33.55–34.40) 35.05 (33.93–36.17) 0.081
Adherence MD (≥34 
score), n (%) 185 (58.0) 22 (64.7) 0.450 166 (57.6) 33 (61.1) 0.635 173 (56.7) 32 (72.7) 0.044
Table 2. General characteristics of the Mugello population, according to genotype. *Mean ± standard deviation.
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Discussion
This is the first study that investigated the role of some CLOCK gene SNPs on the quality of aging in a population 
of very elderly subjects. In the context of the Mugello Study, an epidemiological study aimed at investigating the 
quality of aging in a cohort of nonagenarians, we were able to demonstrate that some SNPs and the relative hap-
lotypes of the CLOCK gene are associated with several traditional cardiovascular risk factors, as with cognitive 
status, the sleep pattern and adherence to the Mediterranean diet, possibly hypothesizing a role of this gene in the 
longevity process.
Aging is a physiological process that determines important changes in organ functions and biological varia-
bles. One of the most significant alterations includes changes in the output rhythms of the circadian clock because 
many physiological variables, including those involved in the metabolism are important to ensure that develop-
ment, survival, and reproduction remain synchronized with environmental changes along the scale of 24-hour19. 
As a result, older individuals typically exhibit a physiological decline in circadian rhythms with many health 
consequences20. The mechanisms underlying these changes are largely unknown, but beyond the changes in the 
neurochemical and electrophysiological output of the central nervous system, a possible association with some 
variations of the CLOCK gene was also reported20. The CLOCK is a protein coded by the CLOCK gene that regu-
lates the circadian rhythm, so it has been reported that some genetic variations in the gene coding for the CLOCK 
protein can influence the circadian rhythm21. Recently, some studies have highlighted a role of the CLOCK gene 
on some aspects of the longevity process, suggesting a possible link between this gene and aging19–21.
In the present study, we found an association between some CLOCK gene polymorphisms and traditional car-
diovascular risk factors such as overweight, glycemia, LDL-cholesterol and triglycerides. To date, cardiovascular 
diseases are the leading cause of morbidity and mortality even in the elderly, as the quality of aging is extremely 
affected by the concomitant presence of a cardiovascular disease or a higher cardiovascular risk profile. As already 
reported by other studies, we confirmed that one of the investigated polymorphism, SNP rs1801260, is related to 
a reduced risk of overweight, probably mediated by the well-known association of the CLOCK gene on the sleep 
pattern, which in turn predisposes to obesity8,22. This was also confirmed by the haplotype analysis, in which it 
emerged that the AAG haplotype was associated with a lower risk of overweight and that the GGC haplotype was 
associated with a better sleep pattern.
Furthermore, we have also shown that other gene polymorphisms, namely rs1801260 and rs11932595, are 
associated with higher levels of fasting glucose and that the GGC (rs1801260-rs11932595-rs4580704) haplotype 
is related to a lower risk of hyperglycemia. These results can be explained by the numerous influences that these 
SNPs have on some metabolic processes such as glucose metabolism. In fact, most of the major CLOCK genes are 
expressed in human pancreatic islets, where insulin is rhythmically secreted, and this regulation contributes to 
glucose homeostasis23. Thus, it can be postulated that the effects of the CLOCK gene on glucose metabolism in the 
Figure 1. Linkage disequilibrium (LD) plot between the three clock circadian regulator (CLOCK) gene 
polymorphisms. Black indicates a strong LD (r2 = 1.0), white indicates no LD (r2 = 0), and gray shading 
indicates intermediate LD. The numbers inside the diamonds represent r2 values × 100.
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peripheral organs may be a mechanism involved in the development of hyperglycemia. Next, we also found an 
association between rs4580704 SNP and higher triglyceride and LDL-cholesterol levels, as well as between AAG 
haplotype and both higher triglyceride and total cholesterol levels. Many years ago, human and rodent studies24,25 
have clearly shown that plasma lipids oscillate following a circadian pattern, and it has recently demonstrated 
that the endogenous circadian clock is the main regulator of these fluctuations in the plasma lipid profile, thus 
hypothesizing a potential involvement of genetic variations of the CLOCK gene26.
In addition to cardiovascular risk factors, we were also able to show significant associations between the stud-
ied SNPs, their relative haplotypes, and other age-related parameters such as cognitive function, depressive state 
and quality of diet. In line with previous findings27, we found that the subjects homozygous for the minor allele 
(GG) of the SNP rs1801260 have worse scores on the depression geriatric scale, thus possibly predisposing more 
significantly to a depressive state. This was also confirmed by the haplotype analysis, in which it emerged that 
the AGC haplotype was associated with a lower risk of depression. This association can be explained by that fact 
that depression, like many other psychiatric disorders, is characterized by anomalies of the circadian rhythm, 
including disturbed sleep/wake cycles and by the evidence connecting the circadian clock and the stress response 
systems28. The circadian CLOCK gene regulates physiological sensitivity to the rhythmic release of glucocorti-
coids, which, in turn, have mutual effects on the protein, as stressful life events or increased vulnerability to stress 
are risk factors for multiple psychiatric disorders including major depressive disorder, modulation of the stress 
response can represent a common mechanism by which circadian CLOCK gene influences psychiatric diseases 
including depression28.
On the other hand, we were able to show, for the first time, that in this particular cohort of elderly subjects, 
the SNPs rs1801260 and rs11932595 of the CLOCK gene are associated with a better score at the clock drawing 
test, suggesting a potential beneficial role of the G allele of these SNPs with respect to visuo-constructional skills 
and to abstract thinking. This can be explained by the fact that, as previously discussed, circadian clock variations 
lead to an altered stress response, in which the glucocorticoids play an important role. The increased release of 
glucocorticoids in response to acute stress, due to an alteration of the circadian clock, leads to increased alertness, 
to the mobilization of glucose and fatty acids, and to a better memory formation28. This was also confirmed by the 
haplotype analysis that showed an association between GGC haplotype and a better score at the MMSE.
Finally, with regard to adherence to the Mediterranean diet, although the MedDiet score was similar among 
the tested SNPs’ genotypes, we found a greater number of adherents who were homozygous for the rs4580704 
minor allele compared to heterozygous and homozygous wild-type. This was also confirmed by the haplotype 
analysis that showed that AAC haplotype was associated with a low degree of adherence to the Mediterranean 
diet. Very recently we reported in the same group of subjects that a greater degree of adherence to Mediterranean 
diet was associated with a reduced risk of depression29, so we can hypothesize a role of the CLOCK gene also in 
the modulation of the depressive status through the modification of the quality of the diet.
This paper presents strengths and limitations. The strengths are the peculiar population of evaluated nona-
genarians and the parameters analyzed. No other study, to the best of our knowledge, has previously studied the 
possible influence of CLOCK gene SNPs on the quality of aging in this particular group of subjects. On the other 
hand, this study has some limitations that must to be considered. First of all, due to the fact that we considered a 
peculiar and valuable cohort of nonagenarians, the number of subjects analyzed was not so large. Second, adher-
ence to prescribed medications was not evaluated, so possibly influencing the results of the study. In addition, the 
results of this study were based on a cross-sectional analysis, which is commonly considered less robust than lon-
gitudinal analyses. However, this limitation is quite common in studies involving the older old as lethality heavily 
affects the availability of participants for follow-ups.
In conclusion, the CLOCK gene seems to have a multi-function that globally and independently of the physi-
ological decay is able to regulate some metabolic and psychiatric parameters in nonagenarians. Indeed, the pres-
ent study suggests an association between the CLOCK gene polymorphisms and their derived haplotypes with 
different cardiovascular risk factors, as well as with the cognitive state, sleep pattern and the adherence to the 
Mediterranean diet in a cohort of very old subjects. These results suggest that the presence of some SNPs, added 
to the physiological desynchronization of the typical circadian rhythm of the elderly, can have a serious impact on 
general health, possibly hypothesizing a role of this gene on the quality of aging.
Data Availability
The datasets analyzed during the current study are available from the corresponding author on reasonable re-
quest.
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